Double-Edged effects of arsenic compounds: Anticancer and carcinogenic effects

Current Drug Metabolism

Volumn 14, Issue 10, 2013, Pages 1029-1041

  Rehman, Kanwal ^a,b   Naranmandura, Hua ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Anticancer; Apoptosis; Arsenic; Carcinogenesis; Differentiation

Indexed keywords

ARSENIC; ARSENIC DERIVATIVE; BUTHIONINE SULFOXIMINE; CASPASE; CYTOCHROME C; HYBRID PROTEIN; ORGANOARSENIC DERIVATIVE; REACTIVE OXYGEN METABOLITE; RETINOIC ACID RECEPTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENIC ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DRUG MECHANISM; HUMAN; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENIC POISONING; ARSENICALS; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OXIDES;

EID: 84891286488     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/13892002113146660116     Document Type: Article

References (187)

1. National Research Council, Arsenic in Drinking Water, National Academy Press, Washington, DC, 1999.
2. National Research Council, Arsenic in Drinking Water 2001 Update, National Academy Press, Washington, DC, 2001.
3. Aposhian, H.V.; Zakharyan, R.A.; Avram, M.D.; Kopplin M.J.; Wollenberg, M.L. Oxidation and detoxification of trivalent arsenic species. Toxicol. Appl. Pharmacol., 2003, 193, 1-8.
4. Francesconi, K.A. Arsenic species in seafood: Origin and human health implications. Pure Appl. Chem., 2010, 82, 373-381.
5. Rossman, T.G.; Klein, C.B. Genetic and epigenetic effects of environmental arsenicals. Metallomics, 2011, 3, 1135-1141.
6. Liu, J.; Waalkes, M.P. Liver is a target of arsenic carcinogenesis. Toxicol. Sci., 2008, 105, 24-32.
7. Tseng, C.H.; Huang, Y.K.; Huang, Y.L.; Chung, C.J.; Yang, M.H.; Chen, C.J.; Hsueh, Y.M. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot diseasehyperendemic villages in Taiwan. Toxicol. Appl. Pharmacol., 2005, 206, 299-308.
8. Shen, Z.X.; Chen, G.Q.; Ni, J.H.; Li, X.S.; Xiong, S.M.; Qiu, Q.Y.; Zhu, J.; Tang, W.; Sun, G.L.; Yang, K.Q.; Chen, Y.; Zhou, L.; Fang, Z.W.; Wang, Y.T.; Ma, J.; Zhang, P.; Zhang, T.D.; Chen, S.J.; Chen, Z.; Wang, Z.Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): 2. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89, 3354-3360.
9. Niu, C.; Yan, H.; Sun, H.P.; Liu, J.X.; Gu, B.W.; Su, X.Y.; Cao, Q.; Waxman, S.; Chen, Z.; Chen, S.J.; Shen, Z.X.; Wang, Z.Y. Treatment of de novo and relapsed acute promyelocytic leukemia patients with arsenic trioxide. Blood, 1998, 92, 678a.
10. Waxman, S.; Anderson, K.C. History of the development of arsenic derivatives in cancer therapy, Oncologist., 2001, 6, 3-10.
11. Kitchin, K.T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol., 2001, 172, 249-261.
12. Vahter, M. Mechanisms of arsenic biotransformation. Toxicology, 2002, 181-182, 211-217.
13. Thomas, D.J. Molecular processes in cellular arsenic metabolism. Toxicol. Appl. Pharmacol., 2007, 222, 365-373.
14. Kligerman, A.D.; Tennant, A.H. Insights into the carcinogenic mode of action of arsenic. Toxicol. Appl. Pharmacol., 2007, 222, 281-288.
15. Rehman, K.; Naranmandura, H. Arsenic Metabolism and Thioarsenicals. Metallomics, 2012, 4, 881-892.
16. Miller, W.H.Jr.; Schipper, H.M.; Lee, J.S.; Singer, J.; Waxman, S. Mechanisms of Action of Arsenic Trioxide. Cancer Res., 2002, 62, 3893-903.
17. Rehman, K.; Chen, Z.; Wang, W.W.; Wang, Y.W.; Sakamoto, A.; Zhang, Y.F.; Suzuki, N.; Naranmandura, H. Mechanisms Underlying the Inhibitory Effects of Arsenic Compounds on Protein Tyrosine Phosphatase (PTP), Toxicol. Appl. Pharmacol., 2012, 263, 273-80.
18. Styblo, M.; Serves, S.V.; Cullen, W.R.; Thomas, D.J. Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem. Res. Toxicol., 1997, 10, 27-33.
19. Muller, S.; Walter, R.D.; Fairlamb, A.H. Differential susceptibility of filarial and human erythrocyte glutathione-reductase to inhibition by the trivalent organic arsenical melarsenoxide. Mol. Biochem. Parasitol., 1995, 71, 211-219.
20. Lin, S.; Del Razo, L.M.; Styblo, M.; Wang, C.Q.; Cullen, W.R.; Thomas, D.J. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem. Res. Toxicol., 2001, 14, 305 - 311.
21. Borgnia, M.; Nielsen, S.; Engel, A.; Agre, P.; Cellular and molecular biology of the aquaporin water channels. Annu. Rev. Biochem., 1999, 68, 425-458.
22. Csanaky, I.; Gregus, Z. Effect of Phosphate Transporter and Methylation Inhibitor Drugs on the Disposition of Arsenate and Arsenite in Rats. Toxicol. Sci., 2001, 63, 29-36.
23. Liu, Z.; Shen, J.; Carbrey, J.M.; Mukhopadhyay, R.; Agre, P.; Rosen, B.P. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 6053-6058.
24. Liu, Z.; Sanchez, M.A.; Jiang, X.; Boles, E.; Landfear, S.M.; Rosen, B.P. Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid. Biochem. Biophys. Res. Commun., 2006, 351, 424-430.
25. Jiang, X.; McDermott, J.R.; Jees, A.A.; Rosen, B.P.; Liu, Z. Trivalent arsenicals and glucose use different translocation pathways in mammalian GLUT1. Metallomics, 2010, 2, 211-219.
26. Tsukaguchi, H.; Weremowicz, S.; Morton, C.C.; Hediger, M.A. Functional and molecular characterization of the human neutral solute channel aquaporin-9, Am. J. Physiol., 1999, 277, F685-F696.
27. Suzuki, K.T.; Tomita, T.; Ogra, Y.; Ohmachi, M. Glutathioneconjugated arsenics in the potential hepato-enteric circulation in rats. Chem. Res. Toxicol., 2001, 14, 1604-1611.
28. Kala, S.V.; Neely, M.W.; Kala, G.; Prater, C.I.; Atwood, D.W.; Rice, J.S.; Lieberman, M.W. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J. Biol. Chem., 2000, 275, 33404-33408.
29. Leslie, E.M.; Haimeur, A.; Waalkes, M.P. Arsenic Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1). J. Biol. Chem. 2004, 279, 32700-32708.
30. Carter, D.E.; Aposhian H.V.; Gandolfi, A.J. The metabolism of inorganic arsenic oxides, gallium arsenide, and arsine: A toxicochemical review. Toxicol. Appl. Pharmacol., 2003, 193, 309-334.
31. Carbrey, J.M.; Song, L.; Zhou, Y.; Yoshinaga, M.; Rojek, A.; Wang, Y.; Liu, Y.; Lujan, H.L.; DiCarlo, S.E.; Nielsen, S.; Rosen, B.P.; Agre, P.; Mukhopadhyay, R. Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice. Proc. Natl. Acad. Sci., USA 2009, 106, 15956-15960.
32. Tenenhouse, H.S. Phosphate transport: Molecular basis regulation and pathophysiology. J. Steroid Biochem. Mol. Bio., 2007, 103, 572-577.
33. Sagawa, H.; Aranami, F.; Kaneko, J.; Tomoe, Y.; Miyamoto, K. The roles of Na/Pi-2 transporters in phosphate metabolism. Bone, 2009, 45, S2-S7.
34. Messens, J.; Silver, S. Arsenate Reduction: Thiol Cascade Chemistry with Convergent Evolution. J. Mol. Bio., 2006, 362, 1-17.
35. Hirano, S.; Cui, X.; Li, S.; Kanno, S.; Kobayashi, Y.; Hayakawa, T.; Shraim, A. Difference in uptake and toxicity of trivalent and pentavalent inorganic arsenic in rat heart microvessel endothelial cells. Arch. Toxicol., 2003, 77, 305-312.
36. Naranmandura, H.; Ibata, K.; Suzuki, K.T. Toxicity of dimethylmonothioarsinic acid toward human epidermoid carcinoma A431 cells. Chem. Res. Toxicol., 2007, 20, 1120-1125.
37. Zakharyan, R.A.; Wildfang, E.; Aposhian, H.V. Enzymatic methylation of arsenic compounds. 3. The marmoset and tamarin, but not the rhesus, monkeys are deficient in methyltransferases that methylate inorganic arsenic. Toxicol. Appl. Pharmacol., 1996, 140, 77-84.
38. Drobna, Z.; Walton, F.S.; Harmon, A.W.; Thomas, D.J.; Styblo, M. Interspecies differences in metabolism of arsenic by cultured primary hepatocytes. Toxicol. Appl. Pharmacol., 2010, 245, 47-56.
39. Naranmandura, H.; Rehman, K.; Le, X.C.; Thomas, D.J. Analytical and Bioanalytical Chemistry. Formation of methylated oxyarsenicals and thioarsenicals in wild-type and arsenic (+ 3 oxidation state) methyltransferase knockout mice exposed to arsenate. Anal. Bioanal. Chem., 2012. DOI 10.1007/s00216-012-6207-0.
40. Naranmandura, H.; Suzuki, N.; Suzuki, K.T. Trivalent Arsenicals Are Bound to Proteins during Reductive Methylation. Chem. Res. Toxicol, 2006, 19, 1010-1018.
41. Mandal, B.K.; Suzuki, K.T. Arsenic round the world: A review. Talanta., 2002, 58, 201-235.
42. Drobna, Z.; Naranmandura, H.; Kubachka, K.M.; Edwards, B.C.; Herbin-Davis, K.; Styblo, M.; Le, X.C.; Creed, J.T.; Maeda, N.; Hughes, M.F.; Thomas, D.J. Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem. Res. Toxicol., 2009, 22, 1713-1720.
43. Challenger, F. Biological methylation. Chem. Rev., 1945, 36, 315-361.
44. Cohen, S.M.; Arnold, L.L.; Eldan, M.; Lewis, A.S.; Beck, B.D. Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit. Rev. Toxicol., 2006, 36, 99-133.
45. Naranmandura, H.; Suzuki, N.; Iwata, K.; Hirano, S.; Suzuki, K.T. Arsenic metabolism and thioarsenicals in hamsters and rats. Chem. Res. Toxicol., 2007, 20, 616-624.
46. Hayakawa, T.; Kobayashi, Y.; Cui, X.; Hirano, S. A new metabolic pathway of arsenite: Arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch. Toxicol., 2005, 79, 183-191.
47. Mass, M.J.; Tennant, A.; Roop, B.C.; Cullen, W.R.; Styblo, M.;Thomas, D.J.; Kligerman, A.D. Methylated trivalent arsenic species are genotoxic. Chem. Res. Toxicol., 2001, 14, 355-361.
48. Naranmandura, H.; Xu, S.; Sawata, T.; Hao, W.H.; Liu, H.; Bu, N.; Ogra, Y.; Lou, Y.J.; Suzuki, N. Mitochondria are the Main Target Organelle for Trivalent Monomethylarsonous Acid (MMAIII)- Induced Cytotoxicity. Chem. Res. Toxicol., 2011, 24, 1094-1103.
49. Naranmandura, H.; Carew, M.W.; Xu, S.; Lee, J.; Leslie, E.; M.; Weinfeld, M.; Le, X.C. Comparative Toxicity of Arsenic Metabolites in Human Bladder Cancer EJ-1 Cells. Chem. Res. Toxicol., 2011, 24, 1586-1596.
50. Naranmandura, H.; Xu, S.; Koike, S.; Pan, L.Q.; Chen, B.; Wang, Y.W.; Rehman, K.; Wu, B.; Chen, Z.; Suzuki, N. The endoplasmic reticulum is a target organelle for trivalent dimethylarsinic acid (DMAIII)-induced cytotoxicity. Toxicol. Appl. Pharmacol., 2012, 260, 241-249.
51. Chen, G.Q.; Shi, X.G.; Tang, W.; Xiong, S.M.; Zhu, J.; Cai, X.; Han, Z.G.; Ni, J.H.; Shi, G.Y.; Jia, P.M.; Liu, M.M.; He, K.L.; Niu, C.; Ma, J.; Zhang, P.; Zhang, T.D.; Paul, P.; Naoe, T.; Kitamura, K.; Miller, W.; Waxman, S.; Wang, Z.Y.; de The, H.; Chen, S.J.; Chen, Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): 1. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 1997, 89, 3345-3353.
52. Bajenova, O.; Tang, B.; Pearse, R.; Feinman, R.; Childs, B.H.; Michaeli, J. RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells. Apoptosis, 2004, 9, 561-571.
53. König, A.; Wrazel, L.; Warrell, R.P.Jr.; Rivi R, Pandolfi PP, Jakubowski A, Gabrilove JL. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood, 1997, 90, 562-570.
54. Lu, D.P.; Qiu, J.Y.; Jiang, B.; Wang Q, Liu KY, Liu YR, Chen SS. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: A pilot report. Blood, 2002, 99, 3136-3143.
55. Ahn, W.S.; Bae, S.M.; Lee, K.H.; Kim, Y.W.; Lee, J.M.; Namkoong, S.E.; Lee, I.P.; Kim, C.K.; Seo, J.S.; Sin, J.I.; Kim, Y.W. Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray ana lysis in SiHa cells. Oncol. Rep., 2004, 12, 573-580.
56. Mann, K.K.; Wallner, B.; Lossos, I.S.; Miller, W.H.Jr. Darinaparsin: A novel organic arsenical with promising anticancer activity. Expert Opin. Investig. Drugs, 2009, 18, 1727-1734.
57. Zhang, X.W.; Yan, X.J.; Zhou, Z.R.; Yang, F.F.; Wu, Z.Y.; Sun, H.B.; Liang, W.X.; Song, A.X.; Lallemand-Breitenbach, V.; Jeanne, M.; Zhang, Q.Y.; Yang, H.Y.; Huang, Q.H.; Zhou, G.B.; Tong, J.H.; Zhang, Y.; Wu, J.H.; Hu, H.Y.; de Thé, H.; Chen, S.J.; Chen, Z. Arsenic Trioxide Controls the Fate of the PML-RAR a Oncoprotein by Directly Binding PML. Science, 2010, 328, 240-243.
58. Niu, C.; Yan, H.; Yu, T.; Sun, H.P.; Liu, J.X.; Li, X.S.; Wu, W.; Zhang, F.Q.; Chen, Y.; Zhou, L.; Li, J.M.; Zeng, X.Y.; Yang, R.R.; Yuan, M.M.; Ren, M.Y.; Gu, F.Y.; Cao, Q.; Gu, B.W.; Su, X.Y.; Chen, G.Q.; Xiong, S.M.; Zhang, T.; Waxman, S.; Wang, Z.Y.; Chen, S.J. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 1999, 94, 3315-3324.
59. Ohnishi, K.; Yoshida, H.; Shigeno, K.; Nakamura, S.; Fujisawa, S.; Naito, K.; Shinjo, K.; Fujita, Y.; Matsui, H.; Takeshita, A.; Sugiyama, S.; Satoh, H.; Terada, H.; Ohno, R. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann. Intern. Med., 2000, 133, 881-885.
60. Yeh, E.T.; Tong, A.T.; Lenihan, D.J.; Yusuf, S.W.; Swafford, J.; Champion, C.; Durand, J.B.; Gibbs, H.; Zafarmand, A.A.; Ewer, M.S. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation, 2004, 109, 3122-3131.
61. Lallemand-Breitenbach, V.; Guillemin, M.C.; Janin, A.; Daniel MT, Degos L, Kogan SC, Bishop JM, de Thé H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med., 1999, 189, 1043-1052.
62. Cai, X.; Shen, Y.L.; Zhu, Q.; Jia, P.M.; Yu, Y.; Zhou, L.; Huang, Y.; Zhang, J.W.; Xiong, S.M.; Chen, S.J.; Wang, Z.Y.; Chen, Z.; Chen, G.Q. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia, 2000, 14, 262-270.
63. Zheng, Y.; Shi, Y.; Tian, C.; Jiang, C.; Jin, H.; Chen, J.; Almasan, A.; Tang, H.; Chen, Q. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene,2004, 23,1239-1247.
64. Ora, I.; Bondesson, L.; Jonsson, C.; Ljungberg J, Pörn-Ares I, Garwicz S, Pâhlman S. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem. Biophys. Res. Commun., 2000, 277, 179-185.
65. Zhu, X.H.; Shen, Y.L.; Jing, Y.K.; Cai, X.; Jia, P.M.; Huang, Y.; Tang, W.; Shi, G.Y.; Sun, Y.P.; Dai, J.; Wang, Z.Y.; Chen, S.J.; Zhang, T.D.; Waxman, S.; Chen, Z.; Chen, G.Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancer Inst., 1999, 91, 772-778.
66. Zhu, J.; Okumura, H.; Ohtake, S.; Nakamura, S.; Nakao, S. The molecular mechanism of arsenic trioxide-induced apoptosis and oncosis in leukemia/lymphoma cell lines. Acta Haematol., 2003, 110, 1-10.
67. Faderl, S.; Talpaz, M.; Estrov, Z.; O'Brien, S.; Kurzrock, R.; Kantarjian, H.M. The biology of chronic myeloid leukemia. N. Engl. J. Med., 1999, 341,164-72.
68. Puccetti, E.; Guller, S.; Orleth, A.; Bruggenolte, N.; Hoelzer, D.; Ottmann, O.G.; Ruthardt M. BCR-ABL mediates arsenic trioxideinduced apoptosis independently of its aberrant kinase activity. Cancer Res., 2000, 60, 3409-3413.
69. Perkins, C.; Kim, C.N.; Fang, G.; Bhalla, K.N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x L. Blood, 2000, 95, 1014-1022.
70. Jabbour, E.; Cortes, J.; Kantarjian, H. Optimal first-line treatment of chronic myeloid leukemia-how to use imatinib and what role for newer drugs. Oncology, 2007, 21, 653-662.
71. McCafferty-Grad, J.; Bahlis, N.J.; Krett, N.; Aguilar, T.M.; Reis, I.; Lee, K.P.; Biose, LH. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol. Cancer Ther., 2003, 2, 1155-1164.
72. Toyokuni, S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol. Int., 1999, 49, 91-102.
73. Mathas, S.; Lietz, A.; Janz, M.; Hinz, M.; Jundt, F.; Scheidereit, C.; Bommert K, Dorken B. Inhibition of NFkappaB essentially contributes to arsenic-induced apoptosis. Blood, 2003, 102, 1028-1034.
74. Zhang, W.; Ohnishi, K.; Shigeno, K.; Fujisawa, S.; Naito, K.; Nakamura, S.; Takeshita, K.; Takeshita, A.; Ohno, R. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia, 1998, 12, 1383-1391.
75. Karlsson, J.; Ora, I.; Porn-Ares, I.; Pahlman, S. Arsenic trioxideinduced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin. Cancer Res., 2004, 10, 3179-3188.
76. Han, B.; Zhou, G.; Zhang, Q.; Zhang J, Wang X, Tang W, Kakudo K. Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. J. Exp. Ther. Oncol., 2004, 4, 335-342.
77. Jin, H.O.; Yoon, S.I.; Seo, S.K.; Lee, H.C.; Woo, S.H.; Yoo, D.H.; Lee, S.J.; Choe, T.B.; An, S.; Kwon, T.J.; Kim, J.I.; Park, M.J.; Hong, S.I.; Park, I.C.; Rhee, C.H. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem. Pharmacol., 2006, 72, 1228-1236.
78. Uslu, R.; Sanli, U.A.; Sezgin, C.; Karabulut B, Terzioglu E, Omay SB, Goker E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res., 2000, 6, 4957-4964.
79. Gallagher, R.; Ferrari, A.; Makower, D. Pilot results from a phase 2 trial of arsenic trioxide in hormone-refractory prostate cancer. Cancer Invest., 2002, 20, 84-85.
80. Li, X.; Ding, X.; Adrian, T.E. Arsenic trioxide inhibits proliferation and induces apoptosis in pancreatic cancer cells. Anticancer Res., 2002, 22, 2205-2213.
81. Aklilu, M.; Kindler, H.L.; Nattam, S.; Brich, A.; Vokes, E.E. A multicenter phase 2 study of arsenic trioxide (AT) in patients (Pts) with advanced pancreatic cancer (PC) refractory to gemcitabine. In: Oncology JoC ed. 2004 ASCO Annual Meeting Proceedings, 2004.
82. Oketani, M.; Kohara, K.; Tuvdendorj, D.; Ishitsuka K, Komorizono Y, Ishibashi K, Arima T. Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett., 2002, 183, 147-153.
83. Lin, J.H.; Li, H.; Yasumura, D.; Cohen, H.R.; Zhang, C.; Panning, B.; Shokat, K.M.; Lavail, M.M.; Walter, P. IRE1 signaling affects cell fate during the unfolded protein response. Science, 2007, 318, 944-949.
84. Kim, K.B.; Bedikian, A.Y.; Camacho, L.H.; Papadopoulos, N.E.; McCullough, C. A Phase 2 Trial of Arsenic Trioxide in Patients with Metastatic Melanoma. Cancer., 2005, 104, 1687-1692.
85. Ivanov, V.N.; Bhoumik, A.; Ronai, Z. Death receptors and melanoma resistance to apoptosis. Oncogene, 2003, 22, 3152-3161.
86. Ivanov, V.N.; Hei, T.K. Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J. Biol. Chem., 2004, 279, 22747-22758.
87. Kindler, H.L.; Aklilu, M.; Nattam, S.; Vokes, E.E. Arsenic Trioxide in Patients With Adenocarcinoma of the Pancreas Refractory to Gemcitabine. Am. J. Clin. Oncol., 2008, 31, 553-556.
88. Subbarayan, P.R.; Lima, M.; Ardalan, B. Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: A clinical experience. Acta Oncologica, 2007, 46, 557-561.
89. Vuky, J.; Yu, R.; Schwartz, L.; Motzer, R.J. Phase 2 trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs, 2002, 20, 327-330.
90. Miller, W.H. Jr.; Schipper, H.M.; Lee, J.S.; Singer, J.; Waxman, S. Mechanisms of action of arsenic trioxide. Cancer. Res., 2002, 62, 389-303.
91. Bael, T.E.; Peterson, B.L.; Gollob, J.A. Phase 2 trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res., 2008, 18, 147-151.
92. Lin, C.C.; Hsu, C.; Hsu, C.H.; Hsu, W.L.; Cheng, A.L.; Yang, C.H. Arsenic trioxide in patients with hepatocellular carcinoma: A phase 2 trial. Invest. New. Drugs, 2006, 25, 77-84.
93. Wu, J.; Henderson, C.; Feun, L.; Van Veldhuizen, P.; Gold, P.; Zheng, H.; Ryan, T.; Blaszkowsky, L.S.; Chen, H.; Costa, M.; Rosenzweig, B.; Nierodzik, M.; Hochster, H.; Muggia, F.; Abbadessa, G.; Lewis, J.; Zhu, A.X. Phase 2 study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest. New. Drugs, 2010, 28, 670 - 676.
94. Quitas-Cardama, A.; Verstovsek, S.; Freireich, E.; Kantarjian, H.; Chen, Y.W.; Zingaro, R. Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. Anticancer Agnets. Med. Chem., 2008, 8, 904 - 908.
95. Perry, R.R.; Mazetta, J.A.; Levin, M.; Barranco, S.C. Glutathione levels and variability in breast tumors and normal tissue. Cancer, 1993, 72, 783-787.
96. Komarnitsky, P.B.; Qu, Z.; Schwartz, B.; Wallner, B. ZIO-101 (Sdimethyl-arsino-glutathione): An oral multi-targeted anti-cancer drug with anti-angiogenic activity [abstract]. American Association for Cancer Research Annual Meeting: Proceedings, 2007, 48.
97. Konig, A.; Wrazel, L.; Warrell, R.P.Jr.; Rivi, R.; Pandolfi, P.P.; Jakubowski, A.; Gabrilove, J.L. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood, 1997, 90, 562-570.
98. Anderson, K.C.; Boise, L.H.; Louie, R.; Waxman, S. Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J., 2002, 8, 12-25.
99. Grad, J.M.; Bahlis, N.J.; Reis, I.; Oshiro, M.M.; Dalton, W.S.; Boise, L.H. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 2001, 98, 805-813.
100. Bahlis, N.J.; McCafferty-Grad, J.; Jordan-McMurry, I.; Neil, J.; Reis, I.; Kharfan-Dabaja, M.; Eckman, J.; Goodman, M.; Fernandez, H.F.; Boise, L.H.; Lee, K.P. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 2002, 8, 3658-3668.
101. Michel, L.; Dupuy, A.; Jean-Louis, F.; Sors, A.; Poupon, J.; Viguier, M.; Musette, P.; Dubertret, L.; Degos, L.; Dombret, H.; Bachelez, H. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J. Invest. Dermatol., 2003, 121, 881-893.
102. Dai, J.; Weinberg, R.S.; Waxman, S.; Jing, Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood, 1999, 93, 268-277.
103. Maeda, H.; Hori, S.; Ohizumi, H.; Segawa, T.; Kakehi, Y.; Ogawa, O.; Kakizuka A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and l-buthionine-sulfoximine. Cell Death Differ., 2004, 11, 737-746.
104. Rosee, L.P.; Johnson, K.; Corbin, A.S.; Stoffregen, E.P.; Moseson, E.M.; Willis, S.; Mauro M.M.; Melo, J.V. Deininger MW, Druker BJ. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Ablpositive cell lines. Blood, 2004, 103, 208-215.
105. Chiu, H.W.; Ho, S.Y.; Guo, H.R.; Wang, Y.J. Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling pathways. Autophagy, 2009, 5, 472-483.
106. Chiu, H.W.; Lin, J.H.; Chen, Y.A.; Ho, S.Y.; Wang, Y.J. Combination treatment with arsenic trioxide and irradiation enhances cellkilling effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis. Autophagy, 2010, 6, 353-365.
107. Chiu, H.W.; Lin, W.; Ho, S.Y.; Wang, Y.J. Synergistic Effects of Arsenic Trioxide and Radiation in Osteosarcoma Cells through the Induction of Both Autophagy and Apoptosis. Radiat. Res., 2011, 175, 547-560.
108. Chiu, H.W.; Chen, Y.A.; Ho, S.Y.; Wang, Y.J. Arsenic trioxide enhances the radiation sensitivity of androgen-dependent andindependent human prostate cancer cells. PloS One, 2012, 7, e31579.
109. Shao, W.; Fanelli, M.; Ferrara, F.F.; Riccioni, R.; Rosenauer, A.; Davison, K.; Lamph, W.W.; Waxman, S.; Pelicci, P.G.; Lo Coco, F.; Avvisati, G.; Testa, U.; Peschle, C.; Gambacorti-Passerini, C.; Nervi, C.; Miller, W.H.Jr. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR α protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst., 1998, 90, 124-133.
110. Yoshino, Y.; Yuan, B.; Miyashita, S.I.; Iriyama, N.; Horikoshi, A.; Shikino, O.; Toyoda, H.; Kaise, T. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal. Bioanal. Chem., 2009, 393, 689-697.
111. Lu, M.; Wang, H.; Li, X.F.; Lu, X.; Cullen, W.R.; Arnold, L.L.; Cohen, S.M.; Le, X.C. Evidence of hemoglobin binding to arsenic as a basis for the accumulation of arsenic in rat blood. Chem. Res. Toxicol., 2004, 17, 1733-1742.
112. Chen, G.Q.; Zhou, L.; Styblo, M.; Walton, F.; Jing, Y.; Weinberg, R.; Chen, Z.; Waxman, S. Methylated Metabolites of Arsenic Trioxide Are More Potent than Arsenic Trioxide as Apoptotic but not Differentiation Inducers in Leukemia and Lymphoma Cells. Cancer Research, 2003, 63, 1853-1859.
113. Kiguchi, T.; Yoshino, Y.; Yuan, B.; Yoshizawa, S.; Kitahara, T.; Akahane, D.; Gotoh, M.; Kaise, T.; Toyoda, H.; Ohyashiki, K. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leukemia Res., 2010, 34, 403-405.
114. Echaniz-Laguna, A.; Benoilid, A.; Vinzio, S.; Fornecker, L.M.; Lannes, B.; Goullé, J.P.; Broly, F. Mousson de Camaret, B. Mitochondrial myopathy caused by arsenic trioxide therapy. Blood, 2012,119, 4272-4274.
115. Miller, W.H.Jr. Molecular Targets of Arsenic Trioxide in Malignant Cells. The Oncologist, 2002, 7, 14-19.
116. Wang, Z.Y., Chen, Z.; Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 2008, 111, 2505-2515.
117. Chen, S.; Fang, Y.; Ma, L.; Liu, S.; Li, X. Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cells. Int. J. Oncol., 2012, 40, 1089-1096.
118. Chen, G.Q.; Zhu, J.; Shi, X.G.; Ni, J.H.; Zhong, H.J.; Si, G.Y.; Jin, X.L.; Tang, W.; Li, X.S.; Xong, S.M.; Shen, Z.X.; Sun, G.L.; Ma, J.; Zhang, P.; Zhang, T.D.; Gazin, C.; Naoe, T.; Chen, S.J.; Wang, Z.Y.; Chen, Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α /PML proteins. Blood, 1996, 88, 1052-1061.
119. Roboz, G.J.; Dias, S.; Lam, G.; Lane, W.J.; Soignet, S.L.; Warrell, R.P.Jr.; Rafii, S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood, 2000, 96, 1525-1530.
120. Cai, X.; Yu, Y.; Huang, Y.; Zhang, L.; Jia, P.M.; Zhao, Q.; Chen, Z.; Tong, J.H.; Dai, W.; Chen, G.Q. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia, 2003, 17, 1333-1337.
121. Larochette, N.; Decaudin, D.; Jacotot, E.; Brenner, C.; Marzo, I.; Susin, S.A.; Zamzami, N.; Xie, Z.; Reed, J.; Kroemer, G. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp. Cell Res., 1999, 249, 413-421.
122. Ninomiya, M.; Kajiguchi, T.; Yamamoto, K.; Kinoshita, T.; Emi, N.; Naoe, T. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. Haematologica. 2006, 91, 1571-1572.
123. Davison, K.; Mann, K.K.; Miller, W.H.Jr. Arsenic trioxide: mechanisms of action. Semin. Hematol., 2002, 39, 3-7.
124. Zheng, J.; Deng, Y.P.; Lin, C.; Fu, M.; Xiao, P.G.; Wu, M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int. J. Cancer, 1999, 82, 286-292.
125. Lu, M.; Levin, J.; Sulpice, E.; Sequeira-Le Grand, A.; Alemany, M.; Caen, J.P.; Han, Z.C. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp. Hematol., 1999, 27, 845-852.
126. Wang, Z.G.; Rivi, R.; Delva, L.; König, A.; Scheinberg, D.A.; Gambacorti-Passerini, C.; Gabrilove, J.L.; Warrell, R.P.Jr.; Pandolfi, P.P. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR α independent manner. Blood, 1998, 92, 1497-1504.
127. Rostami, S.; Abroun, S.; Alimoghaddam, K.; Nourozinia, M.; Chahardouli, B.; Ghavamzade, A. Evaluation of Effect of As2O3 on Cell Growth, Cell Cycle and Apoptosis in Human Leukemia Cell Line HL-60. Int. J. Hematol. Oncol. Stem Cell Res., 2012, 6, 30-35.
128. Liu, Y.; Guyton, K.Z.; Gorospe, M.; Xu, Q.; Lee, J.C.; Holbrook, N.J. Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. Free Radic. Biol. Med., 1996, 21, 771-781.
129. Wang, Z.; Zhou, J.; Lu, X.; Gong, Z.; Le, X.C. Arsenic Speciation in Urine from Acute Promyelocytic Leukemia Patients undergoing Arsenic Trioxide Treatment. Chem. Res. Toxicol., 2004, 17, 95-103.
130. Del Razo, L.M.; Styblo, M.; Cullen, W.R.; Thomas, D.J. Determination of Trivalent Methylated Arsenicals in Biological Matrices. Toxicol. Appl. Pharmacol., 2001, 174, 282-293.
131. IARC, In IARC Monograghs on Evaluation of Carcinogenic Risks of Chemicals to Humans: Overall Evaluations of Carcinogenicity: An Updating of IARC Monograghs 1 to 42, World Health Organization, IARC, Lyon, 1987, Suppl. 7.
132. Cui, X.; Li, S.; Shraim, A.; Kobayashi, Y.; Hayakawa, T.; Kanno, S.; Yamamoto, M.; Hirano, S. Subchronic exposure to arsenic through drinking water alters expression of cancer-related genes in rat liver. Toxicol. Pathol., 2004, 32, 64-72.
133. Rossman, T.G.; Uddin, A.N.; Burns, F.J. Evidence that arsenite acts as a cocarcinogen in skin cancer. Toxicol. Appl. Pharmacol., 2004, 198, 394-404.
134. European Food Safety Authority, Scientific opinion on Arsenic in Food, EFSA Panel on Contaminants in the Food Chain, EFSA J., 2009.
135. Kitchin, K.T. Recent advances in arsenic carcinogenesis: Modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol., 2001, 172, 249-261.
136. Luster, M.I.; Wilmer, J.L.; Germolec, D.R.; Spalding, J.; Yoshida, T.; Gaido, K.; Simeonova, P.P.; Burleson, F.G.; Bruccoleri, A. Role of keratinocyte-derived cytokines in chemical toxicity. Toxicol. Lett., 1995, 82-83, 471-476.
137. Wu, F.; Burns, F.J.; Zhang, R.; Uddin, A.N.; Rossman, T.G. Arsenite-induced alterations of DNA photodamage repair and apoptosis after solar-simulation UVR in mouse keratinocytes in vitro. Environ. Health Perspect., 2005, 113, 983-986.
138. Schuliga, M.; Chouchane, S.; Snow, E.T. Upregulation of glutathione- related genes and enzyme activities in cultured human cells by sublethal concentrations of inorganic arsenic. Toxicol. Sci., 2002, 70, 183-192.
139. Buzard, G.S.; Kasprzak, K.S. Possible roles of nitric oxide and redox cell signaling in metal-induced toxicity and carcinogenesis: A review. J. Environ. Pathol. Toxicol. Oncol., 2000, 19, 179-199.
140. Bernstam, L.; Nriagu, J. Molecular aspects of arsenic stress. J. Toxicol. Environ. Health B Crit. Rev., 2000, 3, 293-322.
141. Kang, Y.H.; Yi, M.J.; Kim, M.J.; Park, M.T.; Bae, S.; Kang, C.M.; Cho, C.K.; Park, I.C.; Park, M.J.; Rhee, C.H.; Hong, S.I.; Chung, H.Y. Lee, Y.S.; Lee, S.J. Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen speciesmediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res., 2004, 64, 8960-8967.
142. Akao, Y.; Nakagawa, Y.; Akiyama, K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett., 1999,455, 59-62.
143. Salazar, A.M.; Ostrosky-Wegman, P.; Menendez, D.; Miranda, E.; Garcia-Carranca A, Rojas E. Induction of p53 protein expression by sodium arsenite. Mutat. Res., 1997, 381, 259-265.
144. Hamadeh, H.K.; Vargas, M.; Lee, E.; Menzel, D.B. Arsenic disrupts cellular levels of p53 and mdm2: A potential mechanism of carcinogenesis. Biochem. Biophys. Res. Commun., 1999, 263, 446-449.
145. Huang, C.; Ma, W.Y.; Li, J.; Dong, Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res., 1999, 59, 3053-3058.
146. Huang, C.; Ma, W.Y.; Li, J.; Hecht, S.S.; Dong, Z. Essential role of p53 in phenethyl isothiocyanate-induced apoptosis. Cancer Res., 1998, 58, 4102-4106.
147. Harvey, M.; Sands, A.T.; Weiss, R.S.; Hegi, M.E.; Wiseman, R.W.; Pantazis, P.; Giovanella, B.C.; Tainsky, M.A.; Bradley, A.; Donehower, L.A. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene, 1993, 8, 2457-2467.
148. Ludwig, S.; Hoffmeyer, A.; Goebeler, M.; Kilian, K.; Häfner, H.; Neufeld, B.; Han, J, Rapp, U.R. The stress inducer arsenite activates mitogen-activated protein kinases extracellular signalregulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway. J. Biol. Chem., 1998, 273, 1917-1922.
149. Cavigelli, M.; Li, W.W.; Lin, A.; Su, B.; Yoshioka, K.; Karin, M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. Embo. J., 1996, 15, 6269-6279.
150. Huang, X.J.; Wiernik, P.H.; Klein, R.S.; Gallagher, R.E. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med. Oncol., 1999, 16, 58-64.
151. Sakurai, T.; Kaise, T.; Matsubara, C. Inorganic and methylated arsenic compounds induce cell death in murine macrophages via different mechanisms. Chem. Res. Toxicol., 1998, 11, 273-283.
152. Ochi, T.; Nakajima, F.; Sakurai, T.; Kaise, T.; Oya-Ohta, Y. Dimethylarsinic acid causes apoptosis in HL-60 cells via interaction with glutathione. Arch Toxicol., 1996, 70, 815-821.
153. Tezuka, M.; Hanioka, K.; Yamanaka, K.; Okada, S. Gene damage induced in human alveolar type (L-132) cells by exposure to dimethylarsinic acid. Biochem. Biophys. Res. Commun., 1993, 191, 1178-1183.
154. Yamanaka, K.; Ohtsubo, K.; Hasegawa, A.; Hayashi, H.; Ohji, H.; Kanisawa, M.; Okada, S. Exposure to dimethylarsinic acid, a main metabolite of inorganic arsenics, strongly promotes tumorigenesis initiated by 4-nitroquinoline 1-oxide in the lungs of mice. Carcinogenesis, 1996, 17, 767-770.
155. Sakurai, T.; Qu, W.; Sakurai, M. H.; Waalkes, M.P. A major human arsenic metabolite, dimethylarsinic acid, requires reduced glutathione to induce apoptosis. Chem. Res. Toxicol., 2002, 15, 629-637.
156. Aposhian, H.V.; Aposhian, M.M. Arsenic toxicology: five questions. Chem. Res. Toxicol., 2006, 19, 1-15.
157. Kitchin, K.T.; Wallace, K. The role of protein binding of trivalent arsenicals in arsenic carcinogenesis and toxicity. J. Inorg. Biochem., 2008, 102, 532-539.
158. Jiang, G.; Gong, Z.; Li, X.F.; Cullen, W.R.; Le, X.C. Interaction of Trivalent Arsenicals with Metallothionein. Chem. Res. Toxicol., 2003, 16, 873-880.
159. Liu, J.; Kadiiska, M.B.; Liu, Y.; Lu, T.; Qu, W.; Waalkes, M.P. Stress-related gene expression in mice treated with inorganic arsenicals. Toxicol. Sci., 2001, 61, 314-320.
160. Romach, E.H.; Zhao, C.Q.; Del Razo, L.M.; Cebrian, M.E.; Waalkes, M.P. Studies on the mechanisms of arsenic-induced selftolerance developed in liver epithelial cells through continuous low-level arsenite exposure. Toxicol. Sci., 2000, 54, 500-508.
161. Naranmandura, H.; Chen, X.; Tanaka, M.; Wang, W.W.; Rehman, K.; Xu, S.; Chen, Z.; Chen, S. Release of Apoptotic Cytochrome c From Mitochondria by Dimethylarsinous Acid Occurs Through Interaction With Voltage-Dependent Anion Channel. In vitro. Toxicol. Sci., 2012, 128, 137-146.
162. Kitchin, K.T.; Wallace, K. Arsenite binding to synthetic peptides based on the Zn finger region and the estrogen binding region of the human estrogen receptor- R. Toxicol. Appl. Pharmacol., 2005, 206, 66-72.
163. Zhou, X.; Sun, X.; Cooper, K.L.; Wang, F.; Liu, K.J.; Hudson, L.G. Arsenite Interacts Selectively with Zinc Finger Proteins Containing C3H1 or C4 Motifs. J. Biol. Chem., 2011, 286, 22855-22863.
164. Piatek, K.; Schwerdtle, T.; Hartwig, A.; Bal, W. Monomethylarsonous Acid Destroys a Tetrathiolate Zinc Finger Much More Efficiently than Inorganic Arsenite: Mechanistic Considerations and Consequences for DNA Repair Inhibition. Chem. Res. Toxicol., 2008, 21, 600-606.
165. Asmuss, M.; Mullenders, L.H.; Hartwig, A. Interference by toxic metal compounds with isolated zinc finger DNA repair protein. Toxicol. Lett., 2000, 112-113, 227-231.
166. Schwerdtle, T.; Walter, I.; Hartwig, A. Arsenite and its biomethylated metabolites interfere with the formation and repair of stable BPDE-induced DNA adducts in human cells and impair XPAzf and Fpg. DNA Repair (Amsterdam), 2003, 2, 1449-1463.
167. Yager, J.W.; Wiencke, J.K.; Inhibition of poly(ADP-ribose) polymerase by arsenite. Mutat. Res., 1997, 386, 345-351.
168. Hartwig, A.; Pelzer, A.; Asmuss, M.; Bürkle, A. Very low concentrations of arsenite suppress poly(ADP-ribosyl)ation in mammalian cells. Int. J. Cancer., 2003, 104, 1-6.
169. Hartwig, A.; Blessing, H.; Schwerdtle, T.; Walter, I. Modulation of DNA repair processes by arsenic and selenium compounds. Toxicology, 2003, 193, 161-169.
170. Shi, H.; Hudson, L.G.; Liu, K.J. Oxidative stress and apoptosis in metal ion-induced carcinogenesis. Free Radical Biol. Med., 2004, 37, 582-593.
171. Kitchin, K.T.; Conolly, R. Arsenic-induced carcinogenesis- oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment. Chem. Res. Toxicol., 2010, 23, 327-335.
172. Yamanaka, K.; Kato, K.; Mizoi, M.; An, Y.; Takabayashi, F.; Nakano, M.; Hoshino, M.; Okada, S. The role of active arsenic species produced by metabolic reduction of dimethylarsinic acid in genotoxicity and tumorigenesis. Toxicol. Appl. Pharmacol., 2004, 198, 385 - 393.
173. Birch-Machin, M.A. The role of mitochondria in ageing and carcinogenesis. Clin. Exp. Dermatol., 2006, 31, 548 - 552.
174. Hirano, S.; Kobayashi, Y.; Cui, X.; Kanno, S.; Hayakawa, T.; Shraim, A. The accumulation and toxicity of methylated arsenicals in endothelial cells: Important roles of thiol compounds. Toxicol. Appl. Pharmacol., 2004, 198, 458-467.
175. Cohen, S.M.; Ohnishi, T.; Arnold, L.L.; Le, X.C. Arsenic-induced bladder cancer in an animal model. Toxicol. Appl. Pharmacol., 2007, 222, 258-263.
176. Ron, D.; Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol., 2007, 8, 519-529.
177. Yoshida, H. ER stress and diseases. FEBS J., 2007, 274, 630-658.
178. Wu, L.L.; Chiou, C.C.p Chang, P.Y.; Wu, J.T. Urinary 8-OHdG: A marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin. Chim. Acta, 2004, 339, 1-9.
179. Wanibuchi, H.; Hori, T.; Meenakshi, V.; Ichihara, T.; Yamamoto, S.; Yano, Y.; Otani, S.; Nakae, D.; Konishi, Y.; Fukushima, S. Promotion of rat hepatocarcinogensesis by dimethylarsinic acid as assessed in rat in vivo models: A review. Mutat. Res., 1997, 386, 353-361.
180. Yamanaka, K.; Mizoi, M.; Kato, K.; Hasegawa, A.; Nakano, M.; Okada, S. Oral administration of dimethylarsinic acid, a main metabolite of inorganic arsenics, promote skin tumorigenesis in mice. Biochem. Biophys. Res. Commun. 2001, 287, 66-70.
181. Abernathy, C.O.; Lui, Y.P.; Longfellow, D.; Aposhian, H.V.; Beck, B.; Fowler, B.; Goyer, R.; Menzer, R.; Rossman, T.; Thompson, C.; Waalkes, M. Arsenic: Health effects, mechanisms of actions and research issues. Environ. Health Perspect., 1999, 107, 593-597.
182. Mass, M.J.; Wang, L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: A model for a mechanism of carcinogenesis. Mutat. Res., 1997, 386, 263-277.
183. Zheng, P.Z.; Wang, K.K.; Zhang, Q.Y.; Huang, Q.H.; Du, Y.Z.; Zhang, Q.H.; Xiao, D.K.; Shen, S.H.; Imbeaud, S.; Eveno, E.; Zhao, C.J.; Chen, Y.L.; Fan, H.Y.; Waxman, S.; Auffray, C.; Jin, G.; Chen, S.J.; Chen, Z.; Zhang, J. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell ifferentiation/apoptosis of promyelocytic leukemia. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 7653-7658.
184. Ong, P.S.; Chan, S.Y.; Ho, P.C. Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As(2)O(3) and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR. Eur. J. Pharm. Sci., 2012, 45, 367-378.
185. Sertel, S.; Tome, M.; Briehl, M.M.; Bauer, J.; Hock, K.; Plinkert, P.K.; Efferth, T. Factors determining sensitivity and resistance of tumor cells to arsenic trioxide. PloS One, 2012, 7, e35584.
186. Soignet, S.L.; Frankel, S.R.; Douer, D.; Tallman, M.S.; Kantarjian, H.; Calleja, E.; Stone, R.M.; Kalaycio, M.; Scheinberg, D.A.; Steinherz, P.; Sievers, E.L.; Coutré, S.; Dahlberg, S.; Ellison, R.; Warrell, R.P.Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol., 2001, 19, 3852-3860.
187. Liu, Q.; Hilsenbeck, S.; Gazitt, Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood, 2003, 101, 4078-4087.